NewAmsterdam Pharma Company NV
NAMS
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.2B
Close$
$2.90
91.3% downside
Current Fair Value
91.3% downsideOvervalued by 91.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.20 Billion |
|---|---|
| Enterprise Value | $3.75 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.75 |
| Beta | 0.08 |
| Outstanding Shares | 121,102,500 |
Return
| Return on Equity | -31.98% |
|---|---|
| Return on Assets | -29.04% |
| Return on Invested Capital | -34.88% |
Valuation & Multiples
| P/E Ratio | -19.48 |
|---|---|
| PEG | -86.38 |
| Price to Sales | - |
| Price to Book Ratio | 6.66 |
| Enterprise Value to Revenue | 165.99 |
| Enterprise Value to EBIT | -16.14 |
| Enterprise Value to Net Income | -18 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.46
Average shareholder expectationRevenue Estimate
$1.09 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-0.48
Average shareholder expectationRevenue Estimate
$1.79 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 184.26% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.13%▼ 107.92% |
|---|---|
| Total Invested | $5.43M▼ 99.86% |
| Investors Holding | 6▼ 175.00% |
ESG Score
No data